LUT014 for the Treatment of Radiation Induced Dermatitis in Breast Cancer Patients
The study will evaluate the safety, tolerability and efficacy of LUT014 gel topically administered in breast cancer patients who developed radiation dermatitis. Subjects enrolled to part 1 will be enrolled to receive the study treatment (open label treatment) for 28 days and will be followed up for 2 months after the completion of study treatment. Subject in Part 2 will be randomized in 1:1 ratio to receive either the study drug or placebo (double-blind treatment) for qd topical application for 28 days and will be followed up for 2 months after the completion of study treatment.
Radiation Dermatitis
DRUG: LUT014 Gel|DRUG: Placebo for LUT014 Gel
Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE (Part 1 subjects), Common Terminology Criteria for Adverse Events Version 5.0, 12 weeks (83 days)|Change in the severity of radiation dermatitis based on self reporting Dermatology QoL questionnaire (Part 2 subjects), Dermatology Life Quality Index questionnaire, 14 Days
Change in the severity of radiation dermatitis assessed by CTCAE (Part 1 subjects), CTCAE grading scale for dermatitis radiation, 12 weeks (83 days)|Change in the severity of radiation dermatitis assessed by RTOG/EORTC (part 1 subjects), Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC), 12 weeks (83 days)|Change in the severity of radiation dermatitis based on self reporting Dermatology QoL questionnaire, Dermatology Life Quality Index questionnaire (part 1 subjects), 12 weeks (83 days)|Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE (Part 2 subjects), CTCAE grading scale for dermatitis radiation, 12 weeks (83 days)
The study will evaluate the safety, tolerability and efficacy of LUT014 gel topically administered in breast cancer patients who developed radiation dermatitis. Subjects enrolled to part 1 will be enrolled to receive the study treatment (open label treatment) for 28 days and will be followed up for 2 months after the completion of study treatment. Subject in Part 2 will be randomized in 1:1 ratio to receive either the study drug or placebo (double-blind treatment) for qd topical application for 28 days and will be followed up for 2 months after the completion of study treatment.